Imaging of pheochromocytoma and paraganglioma

Familial Cancer

Volumn 4, Issue 1, 2005, Pages 61-68

  Brink, I ^a   Hoegerle, S ^a   Klisch, J ^a   Bley, T A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Computed tomography; DOPA PET; FDG PET; Magnetic resonance imaging; Metaiodobenzylguanidin; Paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; COCAINE; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F 18; IONIC CONTRAST MEDIUM; LABETALOL; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; PHENOXYBENZAMINE; POTASSIUM IODIDE; PROPRANOLOL DERIVATIVE; RESERPINE; SODIUM PERCHLORATE; SOMATOSTATIN DERIVATIVE; TRACER; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; ADRENERGIC SYSTEM; ARTIFACT; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE URINE LEVEL; CLIP; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; ISOTOPE LABELING; MEDICAL INFORMATION; METABOLITE; METASTASIS; MORPHOLOGY; NECK; NEURAL CREST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PELVIS; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SCAR; SENSITIVITY AND SPECIFICITY; SURGEON; SURGICAL ANATOMY; SYMPATHETIC GANGLION; TUMOR LOCALIZATION; TUMOR RECURRENCE; WHOLE BODY SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; DIHYDROXYPHENYLALANINE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 19944362186     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-004-2155-y     Document Type: Review

References (52)

1. F. Zak 1954 An expanded concept of glomus tissue NY State J Med. 54 1153
2. C Capella C Riva M Cornaggia 1988 Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas Path Res Pract. 183 176 87
3. UN Riede W. Saeger 1993 Paraganglionäres System UN Riede HW Schaefer Allgemeine und Spezielle Pathologie Thieme Stuttgart, Germany 989 91
4. JL. Parkin 1981 Familial multiple glomus tumors and pheochromocytomas Ann Otol Rhinol Laryngol 1981 90 60 3
5. HPH Neumann B Bausch SR Mc Whinney 2002 Germ-line mutations in nonsyndromic pheochromocytoma N Engl J Med. 346 1459 66
6. HPH Neumann DP Berger G Sigmund 1993 Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease N Engl J Med. 329 1531 8
7. BE Baysal RE Ferell JE Willet-Brozick 2000 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paragangliomas Science. 287 848 51
8. S Gruffermann MW Gillman LR Pasternack 1980 Familial carotid body tumors: case report and epidemiologic review, Cancer. 46 2116 22
9. A Tischler MA. Dichter 1977 Neuroendocrine neoplasm and their cells of origin N Engl J Med. 296 919 25
10. A Chang HS Glazer JK Lee 1987 Adrenal gland: MR imaging Radiology. 163 123 8
11. CL. Schultz 1986 CT and MR of the adrenal glands Semin Ultrasound 7 219 23
12. DG Mitchell M Crovello T Matteucci 1992 Benign adrenocortical masses: Diagnosis with chemical shift MR imaging Radiology. 185 345 51
13. JH Bilbey RF McLoughlin PS Kurkjian 1995 MR imaging of adrenal masses: Value of chemical-shift imaging for distinguishing adenomas from other tumours Am J Roentgenol. 164 637 42
14. DA Bitter DS. Ross 1989 Incidentally discovered adrenal masses Am J Surg. 158 159 61
15. EK Outwater ES Siegelman AB Huang BA. Birnbaum 1996 Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences Radiology 201 880 6
16. SM Arnold R Strecker K Scheffler 2003 Dynamic contrast enhancement of paragangliomas of the head and neck: evaluation with time-resolved 2D MR Eur J Radiol. 7 1608 11
17. JC Varghese PF Hahn N Papanicolaou 1997 MR differentiation of pheochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times Clin Radiol. 52 603 6
18. S Maurea A Cuocolo JC Reynolds 1996 Diagnostic imaging in patients with paragangliomas Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med. 40 365 71
19. WW Mayo-Smith MJ Lee MMJ McNicholas 1995 Characterization of adrenal masses (<5∈cm) by use of chemical shift MR imaging: observer clinical results versus quantitative measures Am J Roentgenol. 165 91 5
20. JP. McGahan 1988 Adrenal gland: MR imaging Radiology. 166 284 5
21. IR Francis MD Gross B Shapiro 1992 Integrated imaging of adrenal disease Radiology. 184 1 13
22. TJ Welch PF Sheedy JA van Heerden 1983 Pheochromocytoma: Value of computed tomography Radiology. 148 501 3
23. WM Manger RW Gifford Jr BB. Hoffman 1985 Pheochromocytoma: a clinical and experimental overview Curr Probl Cancer. 9 1 89
24. JJ Mukherjee PD Peppercorn RH Reznek 1997 Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels Radiology. 202 227 31
25. LE Quint GM Glazer IR Francis 1987 Pheochromocytoma and paraganlioma: comparison of MRI imaging with CT and I-131 MIBG scintigraphy Radiology. 165 89 93
26. MG Velchik A Alavi HY Kressel K. Engelman 1989 Localization of pheochromocytoma: MIGB, CT, and MRI correlation J Nucl Med. 30 328 36
27. DM Wieland JL Wu LE Brown 1980 Radiolabelled adrenergic neuron blocking agents: adrenomedullary imaging with 131I-iodobenzylguanidine J Nucl Med. 21 349 53
28. WH. Beierwaltes 1991 Endocrine imaging: parathyroid, adrenal cortex and medulla, and other endocrine tumors Part II. J Nucl Med. 32 1627 39
29. AJ McEwan B Shapiro JC Sisson 1985 Radioiodobezylguanidine for the scintigraphic location and therapy of adrenergic tumors J Nucl Med 21 349 53
30. L Smets L Loesberg M Janssen 1989 Active uptake and extravesicular storage of metaiodobenzylguanidin in human SK-N-SH cells Cancer Res. 49 2941 4
31. Shapiro B, Gross MD. Radioiodinated MIBG for the diagnostic scintigraphy and internal radiotherapy of neuroendocrine tumors. In: Troncone L (ed): I tumori della cresta neurale. Modena, Italy: Arcadia; 65-94
32. CA. Hoefnagel 1994 Metaiodobenzylguanidin and somatostatin in oncology: role in the management of neural crest tumours Eur J Nucl Med. 21 561 81
33. A Piepsz K Hahn I Roca 1990 A radiopharmaceuticals schedule for imaging in paediatrics Eur J Nucl Med. 17 127 9
34. KK Solanki J BomanjiJ Moyes 1992 A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidin (MIBG) Nucl Med Comm. 13 513 21
35. M Nakajo B Shapiro J Copp 1983 The normal and abnormal distribution of the adrenomedullary imaging agent 131-I-iodobenzylguanidin (131I-MIBG) in man: evaluation by scintigraphy J Nucl Med. 24 672 82
36. 3]-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med. 20 716 31
37. F Tenebaum J Lumbroso M Schlumberger 1995 Comparison of radiolabelled octreotide and metaiodobenzylguanidin (MIBG) scintigraphy in malignant pheochromocytoma J Nucl Med. 36 1 6
38. DJ Kwekkeboom H van Urk BKH Pauw 1993 Octreotide scintigraphy for detection of paragangliomas J Nucl Med. 34 873 8
39. D Kopf A Bockisch H Steinert 1997 Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant pheochromocytoma Clin Endocrinol. 46 39 44
40. Bergström M, Eriksson B, Öberg K et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med 1996; 37: 32-7
41. I Ilias J Yu JA Carrasquillo 2003 Superiority of 6-[(18)f] fluorodopamine positron emission tomography versus [(131)i]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma J Clin Endocrinol Metab. 88 4083 74
42. 18F DOPA whole-body PET - initial results Radiology. 222 507 12
43. 18F] fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma Hypertension. 38 6 8
44. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels Eur J Nucl Med. 28 64 71
45. 18F-DOPA positron emission tomography for the detection of glomus tumours Eur J Nucl Med Mol Imag. 30 689 94
46. 18F-DOPA-PET for detection of gastrointestinal carcinoid tumors Radiology. 220 373 80
47. GW Boland MA Goldberg MJ Lee 1995 Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2(F 18) fluoro-2-deoxy-D-glucose Radiology. 194 131 6
48. 18F-FDG-PET in characterizing adrenal lesions detected on CT or MRI J Nucl Med. 42 1795 9
49. 18F-fluorodeoxyglucose positron emission tomography Am J Roentgenol. 168 1357 60
50. S Maurea C Mainolfi H Wang 1996 Positron emission tomography (PET) with flurodeoxyglucose F 18 in the study of adrenal masses: Comparison of benign and malignant lesions Radiol Medica. 92 782 7
51. BL Shulkin NM Thompson B Shapiro 1999 Pheochromocytomas: imaging with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose PET Radiology. 212 35 41
52. 82Rb J Comp Ass Tomog. 20 312 6